Cite as: J. Nieuwenhuis *et al.*, *Science* 10.1126/science.aao5676 (2017).

Vasohibins encode tubulin detyrosinating activity

Joppe Nieuwenhuis,[1] Athanassios Adamopoulos,[1] Onno B. Bleijerveld,[1] Abdelghani Mazouzi,[1] Elmer Stickel,[1] Patrick Celie,[1] Maarten Altelaar,[1,2] Puck Knipscheer,[3,4] Anastassis Perrakis,[1] Vincent A. Blomen,[1]* Thijn R. Brummelkamp[1,4,5]*

[1]Division of Biochemistry, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, Netherlands. [2]Biomolecular Mass Spectrometry and Proteomics, Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, 3584 CH Utrecht, Netherlands. [3]Hubrecht Institute–KNAW, University Medical Center Utrecht, 3584 CT Utrecht, Netherlands. [4]CGC.nl, Plesmanlaan 121, 1066 CX Amsterdam, Netherlands. [5]CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria.

***Corresponding author. Email: vincent.blomen@scenicbiotech.com (V.A.B.); t.brummelkamp@nki.nl (T.R.B.)**

Tubulin is subjected to a number of posttranslational modifications to generate heterogeneous microtubules. The modifications include removal and ligation of the carboxy-terminal tyrosine of α-tubulin. Whereas enzymes for most modifications have been assigned, the enzymes responsible for detyrosination, an activity observed forty years ago, have remained elusive. We applied a haploid genetic screen to find regulators of tubulin detyrosination. We identified SVBP, a peptide that regulates the abundance of Vasohibins (VASH1 and VASH2). Vasohibins, but not SVBP alone, increased detyrosination of α-tubulin and purified Vasohibins removed the carboxy-terminal tyrosine of α-tubulin. Vasohibins played a cell-type dependent role in detyrosination, but cells also contain an additional detyrosinating activity. Thus Vasohibins, hitherto studied as secreted angiogenesis regulators, constitute a long-sought missing link in the tubulin tyrosination cycle.

Microtubules are crucial constituents of the eukaryotic cytoskeleton, a dynamic structure important for cell shape and intracellular transport, composed of polymerized α- and β-tubulin heterodimers. Extensive enzymatic alterations create heterogeneous microtubules decorated with a variety of posttranslational modifications including acetylation, (poly)glutamylation, (poly)glycylation and polyamination (*1*). Most α-tubulin isoforms encode a tyrosine at their C terminus that can be proteolytically removed and re-ligated. The incorporation of tyrosine, the first described posttranslational modification of tubulin, is carried out by the Tubulin Tyrosine Ligase (TTL) which reverses the detyrosinated α-tubulin state to the translated form (*2*). However, the activity of the detyrosinating enzyme (*3*) which initiates the tyrosination cycle, remains unclear.

Tubulin detyrosination has been implicated in cardiac cell function (*4*), cell migration (*5*), mitosis (*6*), as well as trafficking in neurons (*7*). We applied a genetic approach in haploid human cells (*8*, *9*) to identify tubulin detyrosinating enzymes. In wild-type Hap1 cells detyrosinated α-tubulin could be detected and this signal is increased in *TTL*-deficient Hap1 cells, and in cells treated with the microtubule stabilizing agent paclitaxel (Fig. 1A), indicating that the tyrosination cycle is active in Hap1 cells. Next, mutagenized Hap1 cells were stained with antibodies recognizing the detyrosinated form of α-tubulin following paclitaxel treatment and cells displaying the highest and lowest 1% of detyrosinated α-tubulin levels were isolated by Fluorescence Activated Cell Sorting (FACS). Gene-trap insertion sites were mapped to identify genes that are enriched for mutations in cells exhibiting either high or low levels of α-tubulin detyrosination (Fig. 1B) (*9*). *TTL* was identified as the strongest negative regulator of α-tubulin detyrosination (647 independent gene-trap insertion events mapped in the locus in the "high" cell population versus 11 mutations in the "low" population, Fig. 1C). In addition, we identified both subunits (KATNA1 and KATNB1) of the microtubule severing protein complex Katanin as negative regulators and *CAMSAP2* and *MAP4* as positive regulators in agreement with previous studies (*10–12*). Amongst the genes that were enriched at least 4-fold for mutations in the 'low' channel, Small Vasohibin Binding Protein (SVBP) was identified as the most significant hit (P value = 4×10^{-10}). Using an antibody from a different supplier to enrich for cells with high and low levels of tubulin detyrosination, mutations in *SVBP* were similarly enriched in the population displaying "low" detyrosination (n = 62 independent mutations) whereas no mutations in this locus could be identified in the population displaying "high" detyrosination levels (fig. S1A). Neither *TTL* nor *SVBP* scored as regulators in 10 unrelated genetic screens examining diverse protein phenotypes (fig. S1B), suggesting that SVBP has a specific function in α-tubulin detyrosination.

The interaction of SVBP, encoding a short peptide (66 amino acids), with Vasohibins (*13*) further suggested a possible function of SVBP in tubulin detyrosination. Although

Vasohibins have a predicted transglutaminase-like protease fold (*14*), enzymatic activity has not been demonstrated and substrates have not been proposed. They are found in the cytosol, but are considered to act in the extracellular milieu after secretion through a noncanonical pathway (*13*, *15*, *16*). Mammalian cells contain two Vasohibin paralogs: *VASH1* and *VASH2* (fig. S1, C and D), that may act redundantly. To assess the function of SVBP and Vasohibins in detyrosination, we expressed *SVBP*, *VASH1* and *VASH2* in HeLa cells, a cell line with minimal levels of detyrosinated α-tubulin (*17*) (Fig. 1D). While *SVBP* did not increase detyrosinated α-tubulin, expression of *VASH1* or *VASH2* modestly increased detyrosinated α-tubulin. Co-expression of *SVBP* with Vasohibins increased the abundance (*13*) and solubility (fig. S2) of Vasohibins, and increased detyrosination of α-tubulin further. Thus, SVBP and Vasohibins can increase α-tubulin detyrosination.

To determine whether endogenous Vasohibins affected detyrosination of α-tubulin, we generated single- and double knock out cell lines (fig. S3). Loss of *VASH1* or *VASH2* led to a modest decrease in the amount of detyrosinated tubulin in Hap1 cells and their combined loss led to a further decrease, but not absence, of detyrosinated tubulin (Fig. 2A). The presence of detyrosinated tubulin in Vasohibin-deficient cells could not be attributed by expression *TUBA4A* (fig. S4), an isoform lacking the C-terminal tyrosine. To investigate the role of the Vasohibins in other cell types, we generated both *VASH1*-deficient and *VASH1-2*-deficient cell lines in both HEK293T (fig. S5) as well as in the melanoma-derived cell line CHL-1 (fig. S6). In HEK293T cells, a minimal decrease in detyrosinated α-tubulin was observed in *VASH1* mutant cells, but a substantial decrease was observed in double knock out cells (Fig. 2B). In CHL-1 cells, however, the double knock out cells displayed undetectable levels of detyrosinated α-tubulin (Fig. 2B) and a modest increase in the amount of tyrosinated tubulin (fig. S7A). Thus, Vasohibins are important for α-tubulin detyrosination and cells can also contain Vasohibin-independent detyrosinating activity.

Having identified Vasohibin-dependent and -independent activities, we next sought to determine if these could affect the polymerized microtubule population. Paclitaxel stabilizes microtubules and thereby depletes the amount of free α/β-tubulin dimers that are the substrate for TTL (*18*). Treatment of Hap1, HEK293T, and CHL-1 cells with paclitaxel led to a robust increase in α-tubulin detyrosination. In Hap1 and HEK293T cells deficient for *VASH1* and *VASH2* a similar response was observed, also when translation was inhibited in HEK293T cells using cycloheximide (Fig. 2C and fig. S8), suggesting that the Vasohibin-independent activity affects paclitaxel-stabilized microtubules. Comparative immunoblot analysis showed that Vasohibins mediate at least 97% of α-tubulin detyrosination in CHL-1 cells (fig. S9). Paclitaxel treatment also increased detyrosination in these cells, suggesting that Vasohibins also affect the detyrosination status of polymerized microtubules. To address this further, we stained CHL-1 cells using antibodies directed against α-tubulin, tyrosinated and detyrosinated tubulin (Fig. 2D and fig. S7B). The signal for detyrosinated tubulin was absent in Vasohibin-deficient cells but it co-localized with microtubules in both interphase and mitotic wild-type cells (Fig. 2D and fig. S10). Thus, Vasohibins affect the detyrosination state of polymerized microtubules although their activity appeared not to be absolutely needed for chromosome congression (*6*).

To directly test whether Vasohibins act as transglutaminase peptidases toward tyrosinated α-tubulin we designed VASH1-Cys169 and VASH2-Cys93 mutants, affecting their predicted catalytic site (*14*). Co-expression of VASH1-Cys169Ala and VASH2-Cys93Ala with SVBP showed that these cysteines were essential for Vasohibin-dependent induction of detyrosinated α-tubulin (Fig. 3A).

To study if Vasohibins can produce detyrosinated α-tubulin in vitro, we co-expressed the VASH1:SVBP complex in insect cells (Fig. 3B) and purified a stable and soluble complex. Small Angle X-ray Scattering (SAXS) coupled to Size Exclusion Chromatography (SEC) revealed a well-folded, structurally-robust, elongated complex with 1:1 stoichiometry (fig. S11). Purified VASH1:SVBP reduced the tyrosinated form of tubulin while increasing the detyrosinated form as examined by specific antibodies, with an apparent K_M of ~700 nM on α/β-tubulin (fig. S12). VASH1 alone expressed in small amounts, again suggesting that SVBP is needed for folding and thus solubility of VASH1. Importantly, the in vitro detyrosination rate of VASH1:SVBP is about 2.5-fold higher (P = 0.013) toward GTP-induced polymerized stabilized microtubules, compared to non-treated α/β-tubulin (Fig. 3D). Whereas immunoblot analysis suggested that detyrosinated α-tubulin is generated by Vasohibins, it is a possibility that other reaction products could also be generated including the deglutaminated Δ2- or Δ3-forms of α-tubulin (*19*, *20*). Nano-Liquid chromatography mass spectrometry indicated that VASH1:SVBP detyrosinated α-tubulin without affecting adjacent glutamic acid residues (Fig. 3E). Thus, VASH1 acts as a peptidase to catalyze removal of the C-terminal tyrosine of α-tubulin.

We next designed experiments to study the specificity of Vasohibins. Tubulin isoforms encode for different C-terminal tails. These tails were attached to the C terminus of GFP and co-expressed with *VASH1, VASH1-Cys169Ala* and *VASH2*. All isoforms containing a tyrosine at their C terminus could be detyrosinated; *TUBA8A* which encodes for a C-terminal phenylalanine, could also be modified by Vasohibins (fig. S13). To further determine the substrate specificity, we generated mutants in the TUBA1A/B minimal

substrate. Only variants with a C-terminal tyrosine or phenylalanine were processed by Vasohibins (Fig. 3F), suggesting a requirement for an aromatic ring at the C-terminal position. Extension of the C terminus with a glycine prevented enzymatic conversion by Vasohibins, suggesting that the terminal free carboxyl group is required, and that Vasohibins do not cleave internally. These experiments start to provide a rationale for the specific proteolysis of the C terminus of α-tubulin.

Previously, Vasohibins have been studied as secreted molecules affecting angiogenesis although the mechanism of secretion remains unclear (*21*–*23*). The enzymatic activity described here addresses long-standing questions on the nature of molecules that are able to start the detyrosination-tyrosination cycle. Additional studies are required to address if certain isoforms or modified versions of Vasohibins function specifically inside the cell to detyrosinate tubulin. Although detyrosination was envisioned a simple reaction carried out by a carboxypeptidase, the identification of VASH1, VASH2, the regulating peptide SVBP, and a yet-unidentified activity extend our view on the complexity of this process.

REFERENCES AND NOTES

1. S. Gadadhar, S. Bodakuntla, K. Natarajan, C. Janke, The tubulin code at a glance. *J. Cell Sci.* **130**, 1347–1353 (2017). doi:10.1242/jcs.199471 Medline

2. H. Murofushi, Purification and characterization of tubulin-tyrosine ligase from porcine brain. *J. Biochem.* **87**, 979–984 (1980). doi:10.1093/oxfordjournals.jbchem.a132828 Medline

3. M. E. Hallak, J. A. Rodriguez, H. S. Barra, R. Caputto, Release of tyrosine from tyrosinated tubulin. Some common factors that affect this process and the assembly of tubulin. *FEBS Lett.* **73**, 147–150 (1977). doi:10.1016/0014-5793(77)80968-X Medline

4. P. Robison, M. A. Caporizzo, H. Ahmadzadeh, A. I. Bogush, C. Y. Chen, K. B. Margulies, V. B. Shenoy, B. L. Prosser, Detyrosinated microtubules buckle and bear load in contracting cardiomyocytes. *Science* **352**, aaf0659 (2016). doi:10.1126/science.aaf0659 Medline

5. J. R. Yoon, R. A. Whipple, E. M. Balzer, E. H. Cho, M. A. Matrone, M. Peckham, S. S. Martin, Local anesthetics inhibit kinesin motility and microtentacle protrusions in human epithelial and breast tumor cells. *Breast Cancer Res. Treat.* **129**, 691–701 (2011). doi:10.1007/s10549-010-1239-7 Medline

6. M. Barisic, R. Silva e Sousa, S. K. Tripathy, M. M. Magiera, A. V. Zaytsev, A. L. Pereira, C. Janke, E. L. Grishchuk, H. Maiato, Microtubule detyrosination guides chromosomes during mitosis. *Science* **348**, 799–803 (2015). doi:10.1126/science.aaa5175 Medline

7. C. P. Garnham, A. Roll-Mecak, The chemical complexity of cellular microtubules: Tubulin post-translational modification enzymes and their roles in tuning microtubule functions. *Cytoskeleton* **69**, 442–463 (2012). doi:10.1002/cm.21027 Medline

8. J. E. Carette, C. P. Guimaraes, M. Varadarajan, A. S. Park, I. Wuethrich, A. Godarova, M. Kotecki, B. H. Cochran, E. Spooner, H. L. Ploegh, T. R. Brummelkamp, Haploid genetic screens in human cells identify host factors used by pathogens. *Science* **326**, 1231–1235 (2009). doi:10.1126/science.1178955 Medline

9. M. Brockmann, V. A. Blomen, J. Nieuwenhuis, E. Stickel, M. Raaben, O. B. Bleijerveld, A. F. M. Altelaar, L. T. Jae, T. R. Brummelkamp, Genetic wiring maps of single-cell protein states reveal an off-switch for GPCR signalling. *Nature* **546**, 307–311 (2017). doi:10.1038/nature22376 Medline

10. D. Zhang, K. D. Grode, S. F. Stewman, J. D. Diaz-Valencia, E. Liebling, U. Rath, T. Riera, J. D. Currie, D. W. Buster, A. B. Asenjo, H. J. Sosa, J. L. Ross, A. Ma, S. L. Rogers, D. J. Sharp, *Drosophila* katanin is a microtubule depolymerase that regulates cortical-microtubule plus-end interactions and cell migration. *Nat. Cell Biol.* **13**, 361–370 (2011). doi:10.1038/ncb2206 Medline

11. K. Jiang, S. Hua, R. Mohan, I. Grigoriev, K. W. Yau, Q. Liu, E. A. Katrukha, A. F. M. Altelaar, A. J. R. Heck, C. C. Hoogenraad, A. Akhmanova, Microtubule minus-end stabilization by polymerization-driven CAMSAP deposition. *Dev. Cell* **28**, 295–309 (2014). doi:10.1016/j.devcel.2014.01.001 Medline

12. J. T. Fassett, X. Hu, X. Xu, Z. Lu, P. Zhang, Y. Chen, R. J. Bache, AMPK attenuates microtubule proliferation in cardiac hypertrophy. *Am. J. Physiol. Heart Circ. Physiol.* **304**, H749–H758 (2013). doi:10.1152/ajpheart.00935.2011 Medline

13. Y. Suzuki, M. Kobayashi, H. Miyashita, H. Ohta, H. Sonoda, Y. Sato, Isolation of a small vasohibin-binding protein (SVBP) and its role in vasohibin secretion. *J. Cell Sci.* **123**, 3094–3101 (2010). doi:10.1242/jcs.067538 Medline

14. L. Sanchez-Pulido, C. P. Ponting, Vasohibins: New transglutaminase-like cysteine proteases possessing a non-canonical Cys-His-Ser catalytic triad. *Bioinformatics* **32**, 1441–1445 (2016). doi:10.1093/bioinformatics/btv761 Medline

15. M. Saito, Y. Suzuki, S. Yano, T. Miyazaki, Y. Sato, Proteolytic inactivation of anti-angiogenic vasohibin-1 by cancer cells. *J. Biochem.* **160**, 227–232 (2016). doi:10.1093/jb/mvw030 Medline

16. X. Xue, W. Gao, B. Sun, Y. Xu, B. Han, F. Wang, Y. Zhang, J. Sun, J. Wei, Z. Lu, Y. Zhu, Y. Sato, Y. Sekido, Y. Miao, Y. Kondo, Vasohibin 2 is transcriptionally activated and promotes angiogenesis in hepatocellular carcinoma. *Oncogene* **32**, 1724–1734 (2013). doi:10.1038/onc.2012.177 Medline

17. J. C. Bulinski, J. E. Richards, G. Piperno, Posttranslational modifications of α tubulin: Detyrosination and acetylation differentiate populations of interphase microtubules in cultured cells. *J. Cell Biol.* **106**, 1213–1220 (1988). doi:10.1083/jcb.106.4.1213 Medline

18. A. E. Prota, M. M. Magiera, M. Kuijpers, K. Bargsten, D. Frey, M. Wieser, R. Jaussi, C. C. Hoogenraad, R. A. Kammerer, C. Janke, M. O. Steinmetz, Structural basis of tubulin tyrosination by tubulin tyrosine ligase. *J. Cell Biol.* **200**, 259–270 (2013). doi:10.1083/jcb.201211017 Medline

19. L. Paturle-Lafanechère, B. Eddé, P. Denoulet, A. Van Dorsselaer, H. Mazarguil, J. P. Le Caer, J. Wehland, D. Job, Characterization of a major brain tubulin variant which cannot be tyrosinated. *Biochemistry* **30**, 10523–10528 (1991). doi:10.1021/bi00107a022 Medline

20. C. Aillaud, C. Bosc, Y. Saoudi, E. Denarier, L. Peris, L. Sago, N. Taulet, A. Cieren, O. Tort, M. M. Magiera, C. Janke, V. Redeker, A. Andrieux, M.-J. Moutin, Evidence for new C-terminally truncated variants of α- and β-tubulins. *Mol. Biol. Cell* **27**, 640–653 (2016). doi:10.1091/mbc.E15-03-0137 Medline

21. K. Yoshinaga, K. Ito, T. Moriya, S. Nagase, T. Takano, H. Niikura, H. Sasano, N. Yaegashi, Y. Sato, Roles of intrinsic angiogenesis inhibitor, vasohibin, in cervical carcinomas. *Cancer Sci.* **102**, 446–451 (2011). doi:10.1111/j.1349-7006.2010.01812.x Medline

22. H. Kimura, H. Miyashita, Y. Suzuki, M. Kobayashi, K. Watanabe, H. Sonoda, H. Ohta, T. Fujiwara, T. Shimosegawa, Y. Sato, Distinctive localization and opposed roles of vasohibin-1 and vasohibin-2 in the regulation of angiogenesis. *Blood* **113**, 4810–4818 (2009). doi:10.1182/blood-2008-07-170316 Medline

23. J. Kern, M. Steurer, G. Gastl, E. Gunsilius, G. Untergasser, Vasohibin inhibits angiogenic sprouting in vitro and supports vascular maturation processes in vivo. *BMC Cancer* **9**, 284 (2009). doi:10.1186/1471-2407-9-284 Medline

24. A. E. Carpenter, T. R. Jones, M. R. Lamprecht, C. Clarke, I. H. Kang, O. Friman, D. A. Guertin, J. H. Chang, R. A. Lindquist, J. Moffat, P. Golland, D. M. Sabatini, CellProfiler: Image analysis software for identifying and quantifying cell phenotypes. *Genome Biol.* **7**, R100 (2006). doi:10.1186/gb-2006-7-10-r100 Medline

25. E. K. Brinkman, T. Chen, M. Amendola, B. van Steensel, Easy quantitative assessment of genome editing by sequence trace decomposition. *Nucleic Acids Res.* **42**, e168 (2014). doi:10.1093/nar/gku936 Medline

26. M. P. A. Luna-Vargas, E. Christodoulou, A. Alfieri, W. J. van Dijk, M. Stadnik, R. G. Hibbert, D. D. Sahtoe, M. Clerici, V. D. Marco, D. Littler, P. H. N. Celie, T. K. Sixma, A. Perrakis, Enabling high-throughput ligation-independent cloning and protein expression for the family of ubiquitin specific proteases. *J. Struct. Biol.* **175**, 113–119 (2011). doi:10.1016/j.jsb.2011.03.017 Medline

27. D. Franke, M. V. Petoukhov, P. V. Konarev, A. Panjkovich, A. Tuukkanen, H. D. T. Mertens, A. G. Kikhney, N. R. Hajizadeh, J. M. Franklin, C. M. Jeffries, D. I. Svergun, *ATSAS 2.8*: A comprehensive data analysis suite for small-angle scattering from macromolecular solutions. *J. Appl. Crystallogr.* **50**, 1212–1225 (2017). doi:10.1107/S1600576717007786 Medline

28. J. C. Grigg, A. Ke, Structures of large RNAs and RNA-protein complexes: Toward structure determination of riboswitches. *Methods Enzymol.* **558**, 213–232 (2015). doi:10.1016/bs.mie.2015.02.009

29. R. P. Rambo, J. A. Tainer, Accurate assessment of mass, models and resolution by small-angle scattering. *Nature* **496**, 477–481 (2013). doi:10.1038/nature12070 Medline

30. R. P. Rambo, J. A. Tainer, Characterizing flexible and intrinsically unstructured biological macromolecules by SAS using the Porod-Debye law. *Biopolymers* **95**, 559–571 (2011). doi:10.1002/bip.21638 Medline

31. M. V. Petoukhov, D. I. Svergun, Ambiguity assessment of small-angle scattering curves from monodisperse systems. *Acta Crystallogr. D* **71**, 1051–1058 (2015). doi:10.1107/S1399004715002576 Medline

32. P. V. Konarev, D. I. Svergun, A posteriori determination of the useful data range for small-angle scattering experiments on dilute monodisperse systems. *IUCrJ* **2**, 352–360 (2015). doi:10.1107/S2052252515005163 Medline

33. M. B. Kozin, D. I. Svergun, Automated matching of high- and low-resolution structural models. *J. Appl. Crystallogr.* **34**, 33–41 (2001). doi:10.1107/S0021889800014126

34. N. Ameziane, P. May, A. Haitjema, H. J. van de Vrugt, S. E. van Rossum-Fikkert, D. Ristic, G. J. Williams, J. Balk, D. Rockx, H. Li, M. A. Rooimans, A. B. Oostra, E. Velleuer, R. Dietrich, O. B. Bleijerveld, A. F. Maarten Altelaar, H. Meijers-Heijboer, H. Joenje, G. Glusman, J. Roach, L. Hood, D. Galas, C. Wyman, R. Balling, J. den Dunnen, J. P. de Winter, R. Kanaar, R. Gelinas, J. C. Dorsman, A novel Fanconi anaemia subtype associated with a dominant-negative mutation in RAD51. *Nat. Commun.* **6**, 8829 (2015). doi:10.1038/ncomms9829 Medline

ACKNOWLEDGMENTS

We thank R. Medema, J. van den Berg, H. Janssen and members of the Brummelkamp laboratory for discussions, A. Fish for advice in performing biochemical assays, M. Stadnik-Spiewak for assisting in protein expression experiments, D. Peeper for CHL-1 cells and T. Sixma for carefully reading the manuscript. This was work supported by NWO Vici Grant (016.Vici.170.033), KWF grant (NKI2015-7609), the Cancer Genomics Center (CGC.nl) and the Ammodo KNAW Award 2015 for Biomedical Sciences (to T.R.B.) and by the Netherlands Organization for Scientific Research (NWO) as part of the National Roadmap Large-scale Research Facilities of the Netherlands, Proteins@Work (Project number 184.032.201) to O.B.B. and M.A. and a VIDI grant (723.012.102) to M.A. The HAP1 cell line is available from T.R.B. under a material transfer agreement with the Netherlands Cancer Institute. Sequencing data have been deposited in the NCBI Sequence Read Archive (www.ncbi.nlm.nih.gov/sra) under accession number SRP119153 and processed screen results are accessible in an interactive database (https://phenosaurus.nki.nl/).

SUPPLEMENTARY MATERIALS

www.sciencemag.org/cgi/content/full/science.aao5676/DC1
Materials and Methods
Figs. S1 to S13
Table S1
References (*24*–*34*)

3 August 2017; accepted 3 November 2017
Published online 16 November 2017
10.1126/science.aao5676



Fig. 1. Identification of genetic regulators of tubulin detyrosination in haploid human cells. (**A**) Wild-type Hap1 cells and Hap1 cells deficient for *TTL* were treated with paclitaxel and subjected to immunoblot analysis using antibodies directed against detyrosinated and tyrosinated tubulin and TTL. Total amounts of tubulin were used as loading control. The relative ratios of detyrosinated vs. total α-tubulin levels are indicated. Asterisk indicates that deY-Tubulin signal is not quantifiable. (**B**) Schematic overview of the haploid genetic screen using antibodies detecting detyrosinated tubulin. (**C**) Result of the genetic screen for regulators of α-tubulin detyrosination. The relative mutation frequency in the "high" versus the "low" cell population (referred to as Mutation Index) was plotted against the total amount of insertions mapped per gene. Positive regulators are labeled in yellow, negative regulators in blue. (**D**) HeLa cells transfected with vectors directing the expression of FLAG-tagged *SVBP*, *VASH1*, *VASH2*, or combinations thereof, were subjected to immunoblot analysis.



Fig. 2. VASH1 and VASH2 control tubulin detyrosination and affect the detyrosination status of polymerized microtubules. (**A**) Independent Hap1 cell lines deficient for *VASH1*- or *VASH1* and *VASH2* were generated and subjected to immunoblot analysis. The relative ratios of detyrosinated vs. total α-tubulin levels are indicated. (**B**) Independent HEK293T and CHL-1 cell lines deficient for *VASH1* and/or *VASH2* were generated and subjected to immunoblot analysis. (**C**) Wild-type cells and cell lines deficient for *VASH1* and *VASH2* were treated with paclitaxel and subjected to immunoblot assay as in (A). (**D**) Wild-type CHL-1 cells and CHL-1 cells deficient for *VASH1* and *VASH2* were treated with paclitaxel and stained with antibodies to detect detyrosinated α-tubulin (green) and α-tubulin (red). Blue indicates 4',6-diamidino-2-phenylindole (DAPI) nuclear counterstain. Paclitaxel treatment led to a 1.89x increase in the detyrosination/total tubulin ratio of wild-type cells. Scalebar in merge channel represents 25 μm.



Fig. 3 (preceding page). The catalytic activity of Vasohibins specifically removes the tyrosine residue of α-tubulin. (**A**) HeLa cells were transfected with indicated plasmids and subjected to immunoblot analysis. (**B**) Coomassie staining of a gel loaded with the purified products of SVBP, VASH1, SVBP:VASH1 and SVBP:VASH1-C169A expressed in insect cells. (**C**) In vitro detyrosination assay, using recombinant SVBP, VASH1, VASH1:SVBP and catalytic inactive VASH1:SVBP, using purified HeLa α/β-tubulin as substrate. Tubulin tyrosination and detyrosination levels were determined using immunoblot analysis. (**D**) Purified SVBP-VASH1 was incubated with in vitro generated microtubules from HeLa cells and immunoblot signals were quantified to establish the detyrosination rate, compared to non-treated α/β-tubulin (n = 3). (**E**) nanoLC-MS/MS analysis of HeLa tubulin incubated with catalytic active or inactive SVBP-VASH1 complexes. Extracted ion chromatograms of the detyrosinated and tyrosinated peptides are shown as well as the number of assigned spectra of the respective peptides. (**F**) HEK293T cells were co-transfected with vectors encoding the expression of eGFP molecules with C-terminal extensions corresponding to the C terminus TUBA1A/B with the indicated modifications as well as SVBP and VASH1, VASH2 or catalytic inactive VASH1. Transfected cells were subjected to immunoblot analysis.

Science

Vasohibins encode tubulin detyrosinating activity

Joppe Nieuwenhuis, Athanassios Adamopoulos, Onno B. Bleijerveld, Abdelghani Mazouzi, Elmer Stickel, Patrick Celie, Maarten Altelaar, Puck Knipscheer, Anastassis Perrakis, Vincent A. Blomen and Thijn R. Brummelkamp

published online November 16, 2017

Science (print ISSN 0036-8075; online ISSN 1095-9203) is published by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005.